Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H27FN2O4 |
Molecular Weight | 414.4699 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1=C(C)C=C(C(=O)NC2(CCCCC2)C(O)=O)C(=O)N1CC3=CC=C(F)C=C3
InChI
InChIKey=JIYXOJFSPOFZPY-UHFFFAOYSA-N
InChI=1S/C23H27FN2O4/c1-3-19-15(2)13-18(20(27)25-23(22(29)30)11-5-4-6-12-23)21(28)26(19)14-16-7-9-17(24)10-8-16/h7-10,13H,3-6,11-12,14H2,1-2H3,(H,25,27)(H,29,30)
Shionogi developed S 777469 as a selective cannabinoid 2 receptor agonist for the atopic dermatitis treatment. This drug successfully completed phase II clinical trial, where was evaluate its safety and efficacy in patients with atopic dermatitis. However, information about the further development of S 777469 is not available.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00703573
S-777469 400 mg BID (two 200 mg tablets of S-777469 and two tablets of placebo BID)
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
57331749
Created by
admin on Fri Dec 15 16:19:28 GMT 2023 , Edited by admin on Fri Dec 15 16:19:28 GMT 2023
|
PRIMARY | |||
|
S-777,469
Created by
admin on Fri Dec 15 16:19:28 GMT 2023 , Edited by admin on Fri Dec 15 16:19:28 GMT 2023
|
PRIMARY | |||
|
88NI79737I
Created by
admin on Fri Dec 15 16:19:28 GMT 2023 , Edited by admin on Fri Dec 15 16:19:28 GMT 2023
|
PRIMARY | |||
|
DTXSID301336647
Created by
admin on Fri Dec 15 16:19:28 GMT 2023 , Edited by admin on Fri Dec 15 16:19:28 GMT 2023
|
PRIMARY | |||
|
885496-53-7
Created by
admin on Fri Dec 15 16:19:28 GMT 2023 , Edited by admin on Fri Dec 15 16:19:28 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE INACTIVE (PARENT)